Watanabe, Mitsuru
Nakamura, Yuri
Sato, Shinya
Niino, Masaaki
Fukaura, Hikoaki
Tanaka, Masami
Ochi, Hirofumi
Kanda, Takashi
Takeshita, Yukio
Yokota, Takanori
Nishida, Yoichiro
Matsui, Makoto
Nagayama, Shigemi
Kusunoki, Susumu
Miyamoto, Katsuichi
Mizuno, Masanori
Kawachi, Izumi
Saji, Etsuji
Ohashi, Takashi
Shimohama, Shun
Hisahara, Shin
Nishiyama, Kazutoshi
Iizuka, Takahiro
Nakatsuji, Yuji
Okuno, Tatsusada
Ochi, Kazuhide
Suzumura, Akio
Yamamoto, Ken
Kawano, Yuji
Tsuji, Shoji
Hirata, Makoto
Sakate, Ryuichi
Kimura, Tomonori
Shimizu, Yuko
Nagaishi, Akiko
Okada, Kazumasa
Hayashi, Fumie
Sakoda, Ayako
Masaki, Katsuhisa
Shinoda, Koji
Isobe, Noriko
Matsushita, Takuya
Kira, Jun-ichi
Funding for this research was provided by:
Japan Society for the Promotion of Science (19K07995, 18H06214, 19K07997, 18K07529, 20K07869, 16H02657)
Ministry of Health, Labour and Welfare (H26-Itaku (Nan)-Ippan-050)
Japan Agency for Medical Research and Development (JP16ek0109039)
Article History
Received: 27 March 2020
Accepted: 4 November 2020
First Online: 12 January 2021
Competing interests
: M.W. received speaker honoraria and consultant fees from Novartis Pharma, and received a research grant from JSPS KAKENHI (Grant No. 19K07995). Y. Nakamura received a grant and salary from Mitsubishi Tanabe Pharma, Bayer Yakuhin, Ltd., and the Japan Blood Products Organization, received speaker honoraria from Novartis Pharma and received a grant from JSPS KAKENHI (Grant Nos. 18H06214 and 19K21317). M.N. received consultancy fees, speaking fees and/or honoraria from Novartis Pharma, Mitsubishi Tanabe Pharma, the Takeda Pharmaceutical Company, and Biogen Japan. M. Tanaka received speaker honoraria from Biogen Idec Japan, Takeda Pharma, Novartis Pharma, Eisai and Mitsubishi Tanabe Pharma, and served on the scientific advisory board for Biogen Idec Japan. H.O. is a scientific advisory board member of Biogen Japan and Novartis Pharma, and has received honoraria from Biogen Japan, Novartis Pharma, Mitsubishi Tanabe Pharma, and the Takeda Pharmaceutical Company. I.K. received a grant from JSPS KAKENHI (Grant No. 17K09776), funding for research, travel and/or speaker honoraria from Novartis Pharma, Biogen, Alexion Pharmaceuticals, Bristol-Myers Squibb, Bayer Yakuhin Limited, Mitsubishi Tanabe Pharma, the Takeda Pharmaceutical Company, the Japan Blood Products Organization, Teijin Pharma and Astellas Pharma, and is a scientific advisory board member for Biogen, Novartis Pharma, the Takeda Pharmaceutical Company and Alexion Pharmaceuticals. E.S. received a grant from JSPS KAKENHI (Grant No. 18K15443). T. Ohashi received speaker honoraria from Biogen Japan, Novartis Pharma and the Takeda Pharmaceutical Company. T.I. received a grant from The Japan Epilepsy Research Foundation and research support from Astellas Pharma Inc. Y. Kawano received a grant from JSPS KAKENHI (Grant No. 19K07997). Y.S. received speaker honoraria and consultant fees from Bayer Yakuhin, Biogen Idec Japan, the Takeda Pharmaceutical Company, and Novartis Pharma. K.S. received speaker honoraria from Biogen Idec Japan and the Takeda Pharmaceutical Company. A. Sakoda received grant support from Yazuya. N.I. received grant support from Mitsubishi Tanabe Pharma, Osoegawa Neurology Clinic, Bayer Yakuhin, Ltd., and Japan Blood Products Organization, and received a research grant from JSPS KAKENHI (Grant No. 18K07529). T.M. received speaker honoraria payments from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, and Biogen Japan, and received a research grant from JSPS KAKENHI (Grant No. 20K07869). J.K. received consultant fees, speaking fees and/or honoraria from Novartis Pharma, Mitsubishi Tanabe Pharma, Boehringer Ingelheim, Teijin Pharma, Takeda Pharmaceutical Company, Otsuka Pharmaceutical, Astellas Pharma, Pfizer Japan, Sumitomo Dainippon Pharma, and Eisai, and is supported by grants from JSPS KAKENHI (Grant Nos. 16H02657 and 19H01045), the Japan Agency for Medical Research and Development (AMED) (JP16ek0109039) and Health and Labour Sciences Research Grants on Intractable Diseases (H23-Nanchi-Ippan-017; H26-Nanchitou (Nan)-Ippan-074; H26-Itaku (Nan)-Ippan-050; H29-Nanchitou (Nan)-Ippan-043) and a Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) (20FC1030). The other authors declare no competing interests.